Methods to enable cholesterol catabolism in human monocyte derived macrophages
在人单核细胞衍生的巨噬细胞中实现胆固醇分解代谢的方法
基本信息
- 批准号:8181189
- 负责人:
- 金额:$ 35.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-23 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAnimal ModelArterial Fatty StreakAtherosclerosisBacteriaBacterial GenesBiochemicalCarbon DioxideCardiovascular DiseasesCatabolismCause of DeathCell TherapyCholestanesCholesterolCholesterol EstersClinical TrialsComplexCoronaryDevelopmentDiseaseEnzymesEventGene ExpressionGenesGeneticGenus MycobacteriumGoalsHigh Density LipoproteinsHumanImmune responseIndividualLeadLife StyleLipoproteinsMedicalMethodsMyocardial InfarctionPathway interactionsPhagosomesPlasmaProductionProgressive DiseaseStagingStrokeSystemTestingTransfectionUnited StatesVascular Diseasesage relateddesignexpression vectorfeedinghigh riskinnovationlipid metabolismmacrophagemonocytenovel strategiespreventpromoterresponse
项目摘要
DESCRIPTION (provided by applicant): Atherosclerotic cardiovascular disease (CVD) is the leading cause of death in the United States. CVD originates from aberrations in normal lipid metabolism (some genetic, some lifestyle choices) that result in elevated plasma lipoproteins (principally LDLs) and/or low levels of high-density lipoproteins (HDLs). For many people, CVD is an age dependent, progressive disease that is largely undetected or ignored until an event (i.e. myocardial infarction or stroke) occurs in the later stages of disease. Therefore, current therapies focus on preventing a second event (or a primary event in high risk individuals) by reducing the circulating levels of LDLs and/or increasing HDLs. However, at a biochemical level the inability of macrophages to degrade the cholestane ring of cholesterol is a fundamental component of CVD. If macrophages had the ability to degrade cholesterol, they would not become engorged with cholesterol/cholesterol esters and elicit the maladaptive immune response that leads to the onset and progression of atherosclerosis. Recently, studies of Mycobacteria survival in human macrophages revealed a surprising observation. Mycobacteria feed on cholesterol while contained in the phagosomes of macrophages. Importantly, two enzymes that catalyze cholestane ring opening have been identified. We plan to test the hypothesis that genes encoding enzymes identified in bacteria can be humanized and used to transformation human monocyte derived macrophages, enabling the degradation of phagosome-cholesterol. The main objectives are to: 1) humanize bacterial genes encoding key ring opening enzymes, 2) develop an innovative expressions systems to regulate the expression of these genes in response to changes in cellular levels of cholesterol, and 3) characterize the production and fate of compounds generated following B-ring opening. If this paradigm-challenging hypothesis is true, the proposed studies should lead to the development of an entirely new approach for the medical management of CVD.
PUBLIC HEALTH RELEVANCE: At a basic biochemical level, coronary vascular disease (CVD) occurs because humans do not have enzymes capable of hydrolyzing the cholestane ring of cholesterol. The goal of this proposal is to develop methods to enable cholesterol catabolism in human monocyte derived macrophages.
描述(申请人提供):动脉粥样硬化性心血管疾病(CVD)是美国主要的死亡原因。CVD起源于正常脂代谢的异常(一些基因,一些生活方式的选择),导致血浆脂蛋白(主要是低密度脂蛋白)升高和/或高密度脂蛋白(HDL)水平降低。对许多人来说,心血管疾病是一种年龄相关的进行性疾病,在疾病的后期发生事件(如心肌梗死或中风)之前,基本上没有被发现或被忽视。因此,目前的治疗方法侧重于通过降低低密度脂蛋白的循环水平和/或增加低密度脂蛋白来预防第二次事件(或高危个体的主要事件)。然而,在生化水平上,巨噬细胞不能降解胆固醇的胆烷环是心血管疾病的基本成分。如果巨噬细胞具有降解胆固醇的能力,它们就不会被胆固醇/胆固醇酯充斥,并引发导致动脉粥样硬化发生和发展的非适应性免疫反应。最近,关于分枝杆菌在人巨噬细胞中存活的研究揭示了一个令人惊讶的观察结果。分枝杆菌以胆固醇为食,而胆固醇则位于巨噬细胞的吞噬小体中。重要的是,已经确定了两种催化胆烷开环的酶。我们计划测试这样一个假设,即在细菌中发现的编码酶的基因可以人源化,并用于转化人类单核细胞来源的巨噬细胞,从而能够降解吞噬小体胆固醇。主要目标是:1)将编码关键开环酶的细菌基因人源化,2)开发一种创新的表达系统来调节这些基因的表达,以响应细胞内胆固醇水平的变化,以及3)表征B环开环后产生的化合物的产生和命运。如果这一挑战范式的假说是真的,拟议的研究应该会导致开发一种全新的心血管疾病医疗管理方法。
与公共卫生相关:在基本的生化水平上,冠状动脉血管疾病(CVD)的发生是因为人类没有能够水解胆碱环的胆固醇的酶。这项提议的目标是开发能够在人单核细胞来源的巨噬细胞中进行胆固醇分解代谢的方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD E HONKANEN其他文献
RICHARD E HONKANEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD E HONKANEN', 18)}}的其他基金
Methods to enable cholesterol catabolism in human monocyte derived macrophages
在人单核细胞衍生的巨噬细胞中实现胆固醇分解代谢的方法
- 批准号:
8337404 - 财政年份:2011
- 资助金额:
$ 35.91万 - 项目类别:
Methods to enable cholesterol catabolism in human monocyte derived macrophages
在人单核细胞衍生的巨噬细胞中实现胆固醇分解代谢的方法
- 批准号:
8668135 - 财政年份:2011
- 资助金额:
$ 35.91万 - 项目类别:
Methods to enable cholesterol catabolism in human monocyte derived macrophages
在人单核细胞衍生的巨噬细胞中实现胆固醇分解代谢的方法
- 批准号:
8496113 - 财政年份:2011
- 资助金额:
$ 35.91万 - 项目类别:
Development of a HTS-assay for inhibitors of a type 2C protein phosphatase (PPM
开发 2C 型蛋白磷酸酶抑制剂 (PPM) 的 HTS 测定法
- 批准号:
7993354 - 财政年份:2010
- 资助金额:
$ 35.91万 - 项目类别:
HTP screening for inhibitors of ser/the protein phosphatase 5
Ser/蛋白磷酸酶 5 抑制剂的 HTP 筛选
- 批准号:
7694097 - 财政年份:2009
- 资助金额:
$ 35.91万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 35.91万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 35.91万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 35.91万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 35.91万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 35.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 35.91万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 35.91万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 35.91万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 35.91万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 35.91万 - 项目类别:
Grant-in-Aid for Early-Career Scientists